Understanding the Pharmaceutical Supply Chain
In recent years, some policymakers have suggested the United States is too dependent on imports of certain products from countries like China. With the outbreak of COVID-19, the calls to reshore the supply chain of a number of products, including pharmaceuticals and other medical equipment, have intensified.
Policymakers hoping to usher in a new era of industrial policy should be cautious. Reshoring the entire pharmaceutical supply chain would increase costs for consumers, dampen innovation and hurt the competitiveness of a global industry.
In conjunction with the release of a new R Street white paper exploring all of the major issues surrounding the pharmaceutical supply chain, we invite you to a webinar that will dispel a number of myths and offer positive, concrete ideas that are available to policymakers.
Clark Packard (Moderator)
Resident Fellow and Trade Policy Counsel, R Street Institute
Associate Fellow, R Street Institute
Director of Immigration and Trade Policy, American Action Forum
Recent Work from the Federal Affairs Team